Neuromyelitis Optica (NMO) or Devic’s Disease: A Rare but Serious Neurological Disorder

Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic’s Disease, is an autoimmune demyelinating disorder of the central nervous system. In the past, it was considered a variant of Multiple Sclerosis (MS), but today it is recognized as a distinct disease entity with a similar clinical presentation but different characteristics, causes, and treatment approaches.

The disease can occur at any age, although it is more commonly observed in adults and has a higher prevalence among women. Early diagnosis and timely initiation of appropriate treatment are particularly important, as disease relapses may cause permanent neurological damage.

What Is Neuromyelitis Optica (NMO) or Devic’s Disease?

Neuromyelitis Optica is an autoimmune disorder that affects the central nervous system, namely the brain and spinal cord. It may occur as an isolated condition or in association with other autoimmune diseases.

Specifically, the immune system produces antibodies that mistakenly attack the body's own cells, primarily targeting the optic nerves and spinal cord.

According to studies, a large proportion of patients have detectable serum autoantibodies known as aquaporin-4 (AQP4) antibodies. Aquaporin-4 is a protein located on the surface of astrocytes and functions as a water channel within the cell membrane. When these antibodies attack aquaporin-4, severe inflammation and damage to nerve tissue occur.

In approximately 20–30% of patients, AQP4 antibodies are not detected. Some of these patients instead test positive for antibodies against myelin oligodendrocyte glycoprotein (MOG), known as anti-MOG antibodies.

Clinical Presentation and Symptoms

The symptoms of Neuromyelitis Optica are typically episodic in nature. Clinical manifestations depend on the area of the nervous system affected.

Optic Nerve Involvement (Optic Neuritis)

When the optic nerve is affected, the condition is referred to as optic neuritis and may present with:

• Sudden blurred vision or vision loss in one or both eyes.

• Pain during movement of the affected eye.

• Difficulty perceiving colors.

Spinal Cord Involvement (Myelitis)

When the disease affects the spinal cord, it causes myelitis with symptoms such as:

• Weakness in the upper and/or lower limbs.

• Numbness and loss of sensation in the upper and/or lower limbs.

• Difficulty with walking and balance.

• Bladder dysfunction.

Brain Involvement

In the rare cases where the brain is affected, the most common symptoms include:

• Persistent hiccups.

• Nausea.

• Vomiting.

Diagnosis

The diagnosis of Neuromyelitis Optica requires specialized evaluation by a neurologist. Because many of its symptoms resemble those of other neurological disorders—particularly Multiple Sclerosis—early and accurate diagnosis is essential, as treatment strategies differ significantly.

Following an initial clinical suspicion based on medical history and neurological examination, diagnosis is established through:

• Magnetic Resonance Imaging (MRI) of the brain and spinal cord, demonstrating characteristic demyelinating lesions.

• Blood tests for the detection of AQP4 and MOG antibodies.

• Ophthalmological evaluation to assess optic nerve function.

• Lumbar puncture (spinal tap).

• Comprehensive immunological testing.

Accurate and timely diagnosis is critical because the disease can lead to permanent disability if left untreated.

Treatment and Management

Treatment initially focuses on managing acute relapses. This typically involves intravenous administration of high-dose corticosteroids for 3–5 days, depending on symptom severity, in order to reduce inflammation.

If the patient does not respond adequately, plasmapheresis may be performed. This procedure removes harmful antibodies from the bloodstream.

For the long-term prevention of future relapses, oral immunosuppressive medications are commonly used. In recent years, targeted monoclonal antibody therapies have become available, focusing on specific immune system pathways involved in the disease process.

Supportive treatment may also be necessary, including physiotherapy and medications for spasticity management.

Prognosis

Approximately 10–20% of patients experience only a single episode during their lifetime, a form known as monophasic disease.

However, the majority of patients develop a relapsing form of the disease, with disability accumulating over time.

Without preventive treatment, studies indicate that 30–50% of patients may become wheelchair-dependent or blind within five years.

Conclusion

Neuromyelitis Optica is a rare but serious autoimmune disease of the central nervous system that can significantly affect a patient's vision, mobility, and overall quality of life.

Recognizing the symptoms, obtaining an early diagnosis, and gaining access to modern treatment options can substantially reduce the risk of permanent disability and improve long-term outcomes.

Continuous advances in scientific research provide hope for even more effective therapies in the future, offering new possibilities for people living with this challenging condition.